Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

Nigel H. Greig, David Tweedie, Lital Rachmany, Yazhou Li, Vardit Rubovitch, Shaul Schreiber, Yung Hsiao Chiang, Barry J. Hoffer, Jonathan Miller, Debomoy Lahiri, Kumar Sambamurti, Robert E. Becker, Chaim G. Pick

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5%) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (≥75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI.

Original languageEnglish
JournalAlzheimer's and Dementia
Volume10
Issue number1 SUPPL.
DOIs
StatePublished - 2014

Fingerprint

Incretins
Pharmaceutical Preparations
Wounds and Injuries
Neurodegenerative Diseases
Stroke
Brain Concussion
Blast Injuries
Traumatic Brain Injury
Afghanistan
Cerebrovascular Disorders
Iraq
Glucagon-Like Peptide 1
Mortality
Military Personnel
Neurologic Manifestations
Craniocerebral Trauma
Parkinson Disease
Young Adult
Cause of Death
Alzheimer Disease

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., ... Pick, C. G. (2014). Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimer's and Dementia, 10(1 SUPPL.). https://doi.org/10.1016/j.jalz.2013.12.011

Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. / Greig, Nigel H.; Tweedie, David; Rachmany, Lital; Li, Yazhou; Rubovitch, Vardit; Schreiber, Shaul; Chiang, Yung Hsiao; Hoffer, Barry J.; Miller, Jonathan; Lahiri, Debomoy; Sambamurti, Kumar; Becker, Robert E.; Pick, Chaim G.

In: Alzheimer's and Dementia, Vol. 10, No. 1 SUPPL., 2014.

Research output: Contribution to journalArticle

Greig, NH, Tweedie, D, Rachmany, L, Li, Y, Rubovitch, V, Schreiber, S, Chiang, YH, Hoffer, BJ, Miller, J, Lahiri, D, Sambamurti, K, Becker, RE & Pick, CG 2014, 'Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury', Alzheimer's and Dementia, vol. 10, no. 1 SUPPL.. https://doi.org/10.1016/j.jalz.2013.12.011
Greig, Nigel H. ; Tweedie, David ; Rachmany, Lital ; Li, Yazhou ; Rubovitch, Vardit ; Schreiber, Shaul ; Chiang, Yung Hsiao ; Hoffer, Barry J. ; Miller, Jonathan ; Lahiri, Debomoy ; Sambamurti, Kumar ; Becker, Robert E. ; Pick, Chaim G. / Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. In: Alzheimer's and Dementia. 2014 ; Vol. 10, No. 1 SUPPL.
@article{866af53bedb44240934309c67c4569a6,
title = "Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury",
abstract = "Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5{\%}) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (≥75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI.",
author = "Greig, {Nigel H.} and David Tweedie and Lital Rachmany and Yazhou Li and Vardit Rubovitch and Shaul Schreiber and Chiang, {Yung Hsiao} and Hoffer, {Barry J.} and Jonathan Miller and Debomoy Lahiri and Kumar Sambamurti and Becker, {Robert E.} and Pick, {Chaim G.}",
year = "2014",
doi = "10.1016/j.jalz.2013.12.011",
language = "English",
volume = "10",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

AU - Greig, Nigel H.

AU - Tweedie, David

AU - Rachmany, Lital

AU - Li, Yazhou

AU - Rubovitch, Vardit

AU - Schreiber, Shaul

AU - Chiang, Yung Hsiao

AU - Hoffer, Barry J.

AU - Miller, Jonathan

AU - Lahiri, Debomoy

AU - Sambamurti, Kumar

AU - Becker, Robert E.

AU - Pick, Chaim G.

PY - 2014

Y1 - 2014

N2 - Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5%) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (≥75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI.

AB - Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5%) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (≥75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI.

UR - http://www.scopus.com/inward/record.url?scp=84897845269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897845269&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2013.12.011

DO - 10.1016/j.jalz.2013.12.011

M3 - Article

C2 - 24529527

AN - SCOPUS:84897845269

VL - 10

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1 SUPPL.

ER -